Effect of GKRS treatment on trigeminal nerve diffusivities.

Scalar diffusivity values for each ROI were compared pre and post-treatment, as change from baseline value of 100%. Timepoints for comparison are pre-treatment and 6–7 months post-treatment. S1, S2 timepoints (parentheses) represent values measured at 12 and 14 months respectively. S1 diffusivity values trended towards baseline at 14 months, and paralleled the clinical return to baseline pain levels. S2 remained with stable diffusivity values post-treatment, and no clinical return of trigeminal neuralgia pain. The values of S2 and S3 are bolded, and denote lack of post-treatment MR gadolinium-enhancement. “Target” ROI shows statistically significant decrease in FA and elevated RD (two-tailed t-test. SD = standard deviation, NS = no statistical significance).